Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2001
02/15/2001WO2000057852A3 Methods and compositions for treating solid tumors
02/15/2001WO2000054759A3 Lxr modulators
02/15/2001WO2000053167A3 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
02/15/2001WO2000051571A3 Capsule system
02/15/2001WO2000049144A3 Pyk2 binding proteins
02/15/2001WO2000047198A3 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
02/15/2001WO2000043419A3 Exocytosis pathway proteins and methods of use
02/15/2001WO2000002573A8 Natural composition and method for the treatment of sexual dysfunction
02/15/2001WO2000002549A8 Composition for and method of treating neurological disorders
02/15/2001WO1999066902A8 Injectable pharmaceutical formulations of partricin derivatives
02/15/2001WO1999042102A8 Indole-3-propionic acids, salts and esters thereof used as medicaments
02/15/2001DE19938387A1 Inhibition of topoisomerase I using acetyl-11-keto-beta-boswellic acid, useful as cytostatic agent, e.g. for inducing apoptosis in leukemia cells
02/15/2001DE19938386A1 Selective inhibition of 5-lipoxygenase using acetyl-11-keto-beta-boswellic acid, useful as antiinflammatory agent free of side-effects
02/15/2001DE19938098A1 Production of solid thioctic acid formulations comprises dry granulation or direct tabletting of active agent with adjuvants
02/15/2001DE19937496A1 New 3-aminomethylidene-2-indolinone derivatives useful as kinase inhibitors and antiproliferative agents, e.g. for treating viral infections, tumors, inflammation or autoimmune disease
02/15/2001DE19937350A1 Treating C1q-esterase inhibitor protein synthesis disorders, especially angioneurotic edema, using tibolone, without androgenic and virilization side-effects
02/15/2001DE19936997A1 Verfahren zur Nutzung von Dendrimeren als Multiplikatoren zur Verabreichung von Photosensibilisatoren Procedures for the use of dendrimers as multipliers for administration of photosensitizers
02/15/2001DE19936780A1 Neue Antagonisten von Integrinrezeptoren New antagonists of integrin
02/15/2001DE19936719A1 Substituierte 1,5-Dihydropyrrol-2-on-Derivate Substituted 1,5-dihydropyrrol-2-one derivatives
02/15/2001DE19936672A1 Reinforcing epithelial barrier of vaginal mucosa for prophylaxis of perinatally, sexually or other vaginally transferred infections comprises topical application of retinoic acid or its ester or retinol ester
02/15/2001DE19936521A1 Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate Substituted pyrrolidine-2,3,4-trione-3-oxime Derivatives
02/15/2001CA2403910A1 Headache and colic relief composition with asafetida and method of use thereof
02/15/2001CA2382759A1 Agent for the remedy of neural damage having a nitrogen-containing compound as the active ingredient
02/15/2001CA2381919A1 Novel tryptase inhibitors
02/15/2001CA2381910A1 Novel vitamin d analogues
02/15/2001CA2381846A1 Potentiation of inclusion complex formation of cyclodextrin derivatives
02/15/2001CA2381699A1 Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators
02/15/2001CA2381621A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
02/15/2001CA2381396A1 Polynucleotides and polypeptides encoded thereby
02/15/2001CA2381290A1 Bryostatins, bryopyrans and polyketides: compositions and methods
02/15/2001CA2381284A1 Fhm, a novel member of the tnf ligand supergene family
02/15/2001CA2381260A1 Novel 1,4-benzodiazepine compounds and derivatives thereof
02/15/2001CA2381215A1 P38map kinase inhibitors
02/15/2001CA2381033A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
02/15/2001CA2381008A1 Melanocortin-4 receptor binding compounds and methods of use thereof
02/15/2001CA2380981A1 Fluorene derivatives
02/15/2001CA2380973A1 Substituted pyrrolidine-2-3,4-trione 3-oxime derivatives which are active as nmda receptor antagonists
02/15/2001CA2380759A1 Interleukin-5 inhibiting 6-azauracil derivatives
02/15/2001CA2380678A1 Treatment of inflammatory or malignant disease using dnazymes
02/15/2001CA2380647A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
02/15/2001CA2380312A1 Formulations for parenteral use of estramustine phosphate and albumin
02/15/2001CA2379977A1 Novel integrin receptor antagonists
02/15/2001CA2379608A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods
02/15/2001CA2379335A1 Crystals of the sodium salt of pravastatin
02/15/2001CA2379322A1 Torsemide polymorphs
02/15/2001CA2379302A1 Therapeutic agent for diabetes
02/15/2001CA2379087A1 Antimicrobial histone h1 compositions, kits, and methods of use thereof
02/15/2001CA2379052A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins
02/15/2001CA2379047A1 Nitroxy derivatives of (r) and (s)-carnitine
02/15/2001CA2378990A1 1,4-substituted 4,4-diaryl cyclohexanes
02/15/2001CA2378984A1 Antiviral therapy use of p-glycoprotein modulators
02/15/2001CA2378955A1 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy
02/15/2001CA2378620A1 Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
02/15/2001CA2378572A1 Intravaginal clindamycin ovule composition
02/15/2001CA2378499A1 Cyclic amine ccr3 antagonists
02/15/2001CA2378486A1 Osteogenesis promoter sustained-release paste
02/15/2001CA2378482A1 Use of n-methyl bases of ethanolamine for prevention of cell death induced by oxidative stress
02/15/2001CA2378481A1 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate
02/15/2001CA2378445A1 Use of anti-muscarinic agents for treating skin disorders
02/15/2001CA2378401A1 Implantable active ingredient depot
02/15/2001CA2378315A1 Neuropathy therapeutic agent
02/15/2001CA2378310A1 Arylsulfonamido-substituted hydroxamic acid derivatives
02/15/2001CA2378292A1 A knockout mouse for the tumor suppressor gene anx7
02/15/2001CA2378267A1 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof
02/15/2001CA2378257A1 Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
02/15/2001CA2378241A1 Benzanilides as potassium channel openers
02/15/2001CA2377422A1 Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof
02/15/2001CA2348959A1 Methods of cytoprotection using an enantiomer of estrogen of ischemic damage
02/15/2001CA2346291A1 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-.alpha.-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations
02/14/2001EP1076091A1 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
02/14/2001EP1076057A1 Febrifugine and isofebrifugine and processes for the preparation of both
02/14/2001EP1076055A1 1- (1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
02/14/2001EP1076053A1 3-arylphenyl sulfide derivatives and insecticides and miticides
02/14/2001EP1075839A1 Plasma expander, blood diluent and cryoprotector produced using amylopectin-potato starch
02/14/2001EP1075837A2 Process for the preparation of aqueous formulations for ophthalmic use
02/14/2001EP1075836A2 Skin care of food composition containing N-acetyl-glucosamine
02/14/2001EP1075833A1 Barrier cream
02/14/2001EP1075535A1 A method for diagnosing and treating chronic pelvic pain syndrome
02/14/2001EP1075508A2 Enzymatic nucleic acids molecules which modulate the expressions and/or replication of hepatitis c virus
02/14/2001EP1075496A1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
02/14/2001EP1075493A2 Dna encoding snorf25 receptor
02/14/2001EP1075489A2 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues
02/14/2001EP1075486A1 Method of treating bladder and lower urinary tract syndromes
02/14/2001EP1075484A1 Novel anthracycline derivatives and their preparation
02/14/2001EP1075483A2 Hygromycin a derivatives
02/14/2001EP1075481A1 Monomeric, oligomeric and polymeric knoevenagel condensation products
02/14/2001EP1075478A1 Phenylurea and phenylthio urea derivatives
02/14/2001EP1075477A1 Novel n-oxides
02/14/2001EP1075476A1 Novel benzimidazoles and benzoxazoles
02/14/2001EP1075475A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production
02/14/2001EP1075474A1 Process for making 1,3-disubstituted-4-oxocyclic ureas
02/14/2001EP1075473A1 Process for making 1,3-disubstituted-4-oxocyclic ureas
02/14/2001EP1075472A1 Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists
02/14/2001EP1075471A1 Indolyl derivatives as serotonergic agents
02/14/2001EP1075467A1 Pyrazole derivatives as p-38 map kinase inhibitors
02/14/2001EP1075466A1 Cyclopentanone dihydropyridine compounds useful as potassium channel openers
02/14/2001EP1075278A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY
02/14/2001EP1075277A2 Methods for detecting and inhibiting angiogenesis
02/14/2001EP1075272A1 Methods for treating diabetes by inhibiting gdf-8
02/14/2001EP1075268A1 Use of a fluoride ion vector for preparing a medicine for preventing or treating diseases associated with helicobacter pylori